Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
West China Hospital
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Pfizer
Seagen Inc.
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
Catharina Ziekenhuis Eindhoven
Wake Forest University Health Sciences
Elicio Therapeutics
Pfizer
Roswell Park Cancer Institute
Vejle Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
MedImmune LLC
Rigshospitalet, Denmark
University of Pennsylvania
Duke University
Kyungpook National University Hospital
Kyungpook National University Hospital
GlaxoSmithKline
City of Hope Medical Center
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Eli Lilly and Company
Novartis
M.D. Anderson Cancer Center
Dokuz Eylul University
Weill Medical College of Cornell University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Seoul National University Hospital
City of Hope Medical Center
AstraZeneca
City of Hope Medical Center
Mirati Therapeutics Inc.
HUYABIO International, LLC.
HUYABIO International, LLC.